100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AI155211
Award Date
7/1/20
Completion Date
3/31/23
Dollars Obligated
$1.2M
Overview
Activity
4
Transactions
4
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Immuno Technologies Inc. (XKBBFKJS5796)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38103, USA
Update #1
Update #2
ANTIBODY ISOTYPING FOR DISCRIMINATION OF DISEASE STAGE AND DIAGNOSIS OF EARLY LYME DISEASE.
Posted 6/29/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
ANTIBODY ISOTYPING FOR DISCRIMINATION OF DISEASE STAGE AND DIAGNOSIS OF EARLY LYME DISEASE. - ABSTRACT MORE THAN 3 MILLION TESTS ARE PERFORMED EACH YEAR TO SUPPORT THE LABORATORY DIAGNOSIS OF HUMAN LYME DISEASE (LD). WHILE THE CDC CONVENTIONAL STANDARD TWO-TIER (CSTT) APPROACH FOR SERODIAGNOSIS OF LD HAS WORKED RELATIVELY WELL WHEN USED AS RECOMMENDED, THERE IS PLENTY OF ROOM FOR IMPROVEMENT. OF A NUMBER OF WEAKNESSES ASSOCIATED WITH THE SUPPLEMENTAL IMMUNOBLOT OF THE CSTT THE MOST SIGNIFICANT IS LOW REPRODUCIBILITY DUE TO THE SUBJECTIVE VISUAL INTERPRETATION OF RESULTS. TO OVERCOME THESE WEAKNESSES THE CDC RECENTLY UPDATED ITS RECOMMENDATIONS BASED ON A MODIFIED STT (MSTT) IN THAT A SECOND EIA CAN REPLACE THE IMMUNOBLOT. THE MAJOR GOAL OF THIS PROJECT IS TO DEVELOP AN OBJECTIVE, QUANTITATIVE, MULTIPLEX EIA THAT CAN DETECT FOUR ANTIBODY ISOTYPES (IGM/D/G/A) AND ALL FOUR IGG SUBCLASSES (IGG1/2/3/4) TO LEVERAGE ACQUISITION OF SIMULTANEOUS ANTIBODY PROFILE INFORMATION ON MULTIPLE B. BURGDORFERI ANTIGENS TO BUILD AN ASSAY THAT CAN DISCRIMINATE LYME DISEASE STAGE WITH INCREASED OVERALL SENSITIVITY WITHOUT INCURRING IN LOSS OF SPECIFICITY. THE NOVELTY OF THIS STUDY RELIES ON: 1) EVALUATION OF B. BURGDORFERI ANTIGEN-SPECIFIC ANTIBODY ISOTYPES AND IGG SUBCLASSES THAT CAN BE CORRELATED WITH LYME DISEASE STAGE; AND 2) DEVELOPMENT OF NEW DIAGNOSTIC TOOLS USING MACHINE LEARNING TECHNIQUES TO TRAIN AND INTEGRATE ALL DATA AND PRODUCE AN OBJECTIVE RESULT TO DISCRIMINATE EARLY LYME FROM EARLY DISSEMINATED/LATE LYME DISEASE. WE EXPECT THIS PHASE I SBIR TO ALLOW US TO DEVELOP A NEW EIA FOR SERODIAGNOSIS OF LYME DISEASE (ISOEIAPLEX-LD) AND TO FURTHER AN ONGOING COLLABORATION WITH DCN DIAGNOSTICS FOR THE ADAPTATION OF OUR BIOMARKERS TO A NEW RAPID LATERAL FLOW ASSAY (SEE LETTER OF SUPPORT) FOR A FOLLOW UP PHASE II SBIR .
$0
1/29/24
Not listed
ANTIBODY ISOTYPING FOR DISCRIMINATION OF DISEASE STAGE AND DIAGNOSIS OF EARLY LYME DISEASE. - ABSTRACT MORE THAN 3 MILLION TESTS ARE PERFORMED EACH YEAR TO SUPPORT THE LABORATORY DIAGNOSIS OF HUMAN LYME DISEASE (LD). WHILE THE CDC CONVENTIONAL STANDARD TWO-TIER (CSTT) APPROACH FOR SERODIAGNOSIS OF LD HAS WORKED RELATIVELY WELL WHEN USED AS RECOMMENDED, THERE IS PLENTY OF ROOM FOR IMPROVEMENT. OF A NUMBER OF WEAKNESSES ASSOCIATED WITH THE SUPPLEMENTAL IMMUNOBLOT OF THE CSTT THE MOST SIGNIFICANT IS LOW REPRODUCIBILITY DUE TO THE SUBJECTIVE VISUAL INTERPRETATION OF RESULTS. TO OVERCOME THESE WEAKNESSES THE CDC RECENTLY UPDATED ITS RECOMMENDATIONS BASED ON A MODIFIED STT (MSTT) IN THAT A SECOND EIA CAN REPLACE THE IMMUNOBLOT. THE MAJOR GOAL OF THIS PROJECT IS TO DEVELOP AN OBJECTIVE, QUANTITATIVE, MULTIPLEX EIA THAT CAN DETECT FOUR ANTIBODY ISOTYPES (IGM/D/G/A) AND ALL FOUR IGG SUBCLASSES (IGG1/2/3/4) TO LEVERAGE ACQUISITION OF SIMULTANEOUS ANTIBODY PROFILE INFORMATION ON MULTIPLE B. BURGDORFERI ANTIGENS TO BUILD AN ASSAY THAT CAN DISCRIMINATE LYME DISEASE STAGE WITH INCREASED OVERALL SENSITIVITY WITHOUT INCURRING IN LOSS OF SPECIFICITY. THE NOVELTY OF THIS STUDY RELIES ON: 1) EVALUATION OF B. BURGDORFERI ANTIGEN-SPECIFIC ANTIBODY ISOTYPES AND IGG SUBCLASSES THAT CAN BE CORRELATED WITH LYME DISEASE STAGE; AND 2) DEVELOPMENT OF NEW DIAGNOSTIC TOOLS USING MACHINE LEARNING TECHNIQUES TO TRAIN AND INTEGRATE ALL DATA AND PRODUCE AN OBJECTIVE RESULT TO DISCRIMINATE EARLY LYME FROM EARLY DISSEMINATED/LATE LYME DISEASE. WE EXPECT THIS PHASE I SBIR TO ALLOW US TO DEVELOP A NEW EIA FOR SERODIAGNOSIS OF LYME DISEASE (ISOEIAPLEX-LD) AND TO FURTHER AN ONGOING COLLABORATION WITH DCN DIAGNOSTICS FOR THE ADAPTATION OF OUR BIOMARKERS TO A NEW RAPID LATERAL FLOW ASSAY (SEE LETTER OF SUPPORT) FOR A FOLLOW UP PHASE II SBIR .
$295.5k
6/30/21
Not listed
ANTIBODY ISOTYPING FOR DISCRIMINATION OF DISEASE STAGE AND DIAGNOSIS OF EARLY LYME DISEASE. - ABSTRACT MORE THAN 3 MILLION TESTS ARE PERFORMED EACH YEAR TO SUPPORT THE LABORATORY DIAGNOSIS OF HUMAN LYME DISEASE (LD). WHILE THE CDC CONVENTIONAL STANDARD TWO-TIER (CSTT) APPROACH FOR SERODIAGNOSIS OF LD HAS WORKED RELATIVELY WELL WHEN USED AS RECOMMENDED, THERE IS PLENTY OF ROOM FOR IMPROVEMENT. OF A NUMBER OF WEAKNESSES ASSOCIATED WITH THE SUPPLEMENTAL IMMUNOBLOT OF THE CSTT THE MOST SIGNIFICANT IS LOW REPRODUCIBILITY DUE TO THE SUBJECTIVE VISUAL INTERPRETATION OF RESULTS. TO OVERCOME THESE WEAKNESSES THE CDC RECENTLY UPDATED ITS RECOMMENDATIONS BASED ON A MODIFIED STT (MSTT) IN THAT A SECOND EIA CAN REPLACE THE IMMUNOBLOT. THE MAJOR GOAL OF THIS PROJECT IS TO DEVELOP AN OBJECTIVE, QUANTITATIVE, MULTIPLEX EIA THAT CAN DETECT FOUR ANTIBODY ISOTYPES (IGM/D/G/A) AND ALL FOUR IGG SUBCLASSES (IGG1/2/3/4) TO LEVERAGE ACQUISITION OF SIMULTANEOUS ANTIBODY PROFILE INFORMATION ON MULTIPLE B. BURGDORFERI ANTIGENS TO BUILD AN ASSAY THAT CAN DISCRIMINATE LYME DISEASE STAGE WITH INCREASED OVERALL SENSITIVITY WITHOUT INCURRING IN LOSS OF SPECIFICITY. THE NOVELTY OF THIS STUDY RELIES ON: 1) EVALUATION OF B. BURGDORFERI ANTIGEN-SPECIFIC ANTIBODY ISOTYPES AND IGG SUBCLASSES THAT CAN BE CORRELATED WITH LYME DISEASE STAGE; AND 2) DEVELOPMENT OF NEW DIAGNOSTIC TOOLS USING MACHINE LEARNING TECHNIQUES TO TRAIN AND INTEGRATE ALL DATA AND PRODUCE AN OBJECTIVE RESULT TO DISCRIMINATE EARLY LYME FROM EARLY DISSEMINATED/LATE LYME DISEASE. WE EXPECT THIS PHASE I SBIR TO ALLOW US TO DEVELOP A NEW EIA FOR SERODIAGNOSIS OF LYME DISEASE (ISOEIAPLEX-LD) AND TO FURTHER AN ONGOING COLLABORATION WITH DCN DIAGNOSTICS FOR THE ADAPTATION OF OUR BIOMARKERS TO A NEW RAPID LATERAL FLOW ASSAY (SEE LETTER OF SUPPORT) FOR A FOLLOW UP PHASE II SBIR .
$295.5k
6/30/21
Not listed
ANTIBODY ISOTYPING FOR DISCRIMINATION OF DISEASE STAGE AND DIAGNOSIS OF EARLY LYME DISEASE.
$298.1k
6/29/20